Impulse Dynamics: The company raised $158 million of venture funding from Redmile Group, Sands Capital and Perceptive Advisors on December 10, 2025. Alger, Braidwell and other undisclosed investors also participated in the round. The company is a developer of a cardiac contractility modulation technology designed to treat chronic heart failure problems.

BlossomHill Therapeutics: The company raised $84 million of Series B venture funding in a deal led by Brahma Capital, BioTrack Capital and Janus Henderson Investors on December 10, 2025. Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules Bioventures, Plaisance Capital Management, H&D Asset Management and Colt Ventures also participated in the round. The company is an operator of a biopharmaceutical business designed to develop treatments for oncology and autoimmune diseases.

Edison Scientific: The company raised $65.8 million of venture funding from undisclosed investors on December 9, 2025. The company is a developer of AI-powered autonomous research platforms providing literature synthesis, data analysis, and hypothesis generation for scientific discovery.

Relation: The company closed on $55 million of an undisclosed targeted amount of venture funding on December 9, 2025. The company is a provider of biotechnology therapeutics for diseases with significant unmet medical needs across multiple therapeutic areas.

Cresilon: The company raised $48.6 million of Series A venture funding from Catalio Capital Management, William Paseman and other undisclosed investors on December 8, 2025. The company is a developer of plant-based hemostatic gel products promoting natural clotting and rapid wound healing for trauma care.

PsiThera: The company raised $47.5 million of Series A venture funding in a deal led by Lightstone Ventures and Samsara BioCapital on December 10, 2025. Eurofarma Ventures, Roivant Sciences and YK Bioventures also participated in the round. The company is a developer of physics-driven drug discovery platforms accelerating therapeutic design through computational modeling.

EpilepsyGTX: The company raised $33 million of Series A venture funding from British Business Bank, XGEN Venture and other undisclosed investors on December 10, 2025. The company is a developer of gene therapies designed for neurological disorder treatment.

Alphyn: The company raised $25 million of Series B venture funding in a deal led by Queen City Angels on December 12, 2025. Serial Stage Venture Partners, Angel Star Ventures and other undisclosed investors also participated in the round. The company is a developer of bioactive therapeutics for severe and prevalent skin diseases including inflammatory conditions.

Cambrian Bio: The company raised $23 million of venture funding from Korify Capital, FJ Labs and Sprint VC on December 12, 2025. Calm Ventures, Mount Nebo Capital, Gaingels, Shake and Bake, Care Bear, Richard Dulude, RA Capital Management and SV Pacific Ventures also participated in the round. The company is a developer of therapeutics targeting biological mechanisms of aging and age-related disease prevention.

Relentless Health: The company raised $20.7 million of venture funding from undisclosed investors on December 9, 2025. The company is an operator of an artificial intelligence health data platform intended to facilitate early disease prevention through predictive analytics.

Bioxodes: The company raised EUR 17.5 million of Series A venture funding from Newton BioCapital and other undisclosed investors on December 10, 2025. The company is an operator of a clinical-stage biopharmaceutical business intended to prevent and treat thrombotic and inflammatory diseases.

Consano Bio: The company raised $16.8 million of venture funding in the form of convertible debt from undisclosed investors on December 12, 2025. The company is a developer of biologic therapeutics for orthopedic conditions, providing disease-modifying cartilage regeneration treatments.

Pan Cancer T: The company raised EUR 10 million of venture funding from Erasmus MC, InnovationQuarter, and Thuja Capital Management on December 8, 2025. Van Herk Groep also participated in the round. The company is a developer of T-cell therapies designed to provide treatment options for hard-to-treat solid cancers through adoptive therapy.

Lin Health: The company raised $11 million of Series A venture funding in a deal led by Proofpoint on December 9, 2025, putting the company’s pre-money valuation at $29 million. Viola Ventures, Saban Ventures, Mayo Clinic Ventures, NewHealth Ventures, Osage Venture Partners, Shoni Health Ventures and aMoon Fund also participated in the round. The company is a developer of a digital, integrated behavioral health therapy platform designed to offer diagnosis and treatment for people suffering from chronic pain.

uMethod: The company raised $4.5 million of venture funding in the form of convertible debt from undisclosed investors on December 8, 2025. The company is a provider of evidence-based, personalized treatment plan services intended to treat chronic diseases.

NeuroBionics: The company raised $4.25 million of venture funding from undisclosed investors on December 10, 2025. The company is a developer of a neural interface technology designed to enhance the integration of bioelectronics with the human body.

Auxilium Biotechnologies: The company raised $3.9 million of venture funding from undisclosed investors on December 11, 2025, putting the company’s pre-money valuation at $88.7 million. The company is an operator of a biotechnology business intended to treat traumatic injuries of the nervous system.

Etheros Pharmaceuticals: The company raised an undisclosed amount of venture funding from Backed VC and Immortal Dragons on December 9, 2025. The company is a developer of small-molecule drugs designed to mimic endogenous enzymes for neuroprotection and healthspan improvement.

InduPro: The company raised an undisclosed amount of venture funding from Sanofi on December 10, 2025. The company is an operator of a biopharma business intended to manipulate protein pairings via induced protein proximity to create novel signaling pathways and logic gates.

Noah Labs: The company raised an undisclosed amount of venture funding from Catalpa Ventures on December 9, 2025. The company is a developer of software-based medical devices designed to offer voice-based machine learning software for the early detection of heart failure.

Ryght AI: The company raised an undisclosed amount of venture funding from Accenture on December 11, 2025. The company is a developer of an enterprise-scale platform designed to utilize generative artificial intelligence for real-time biopharma discovery.

Senderra RX Partners: The company entered into a definitive agreement to receive an undisclosed amount of development capital from Nautic Partners on December 10, 2025. The company is a U.S. provider of specialty pharmacy services serving patients, prescribers, payers, and pharmaceutical partners.

Stellus Rx: The company received an undisclosed amount of development capital from WindRose Health Investors on December 8, 2025. The company is a provider of personalized pharmacy services intended to serve patients, healthcare providers, and risk-bearing entities.

Merus / Genmab: The company was acquired by Genmab for approximately $7.4 billion on December 12, 2025. Merus NV is a clinical-stage immuno-oncology company that develops bispecific antibody therapeutics.

Orbital Therapeutics / Bristol-Myers Squibb: The company was acquired by Bristol-Myers Squibb for $1.5 billion on December 8, 2025. The company is a developer of RNA therapeutics platforms integrating delivery mechanisms and modalities for genetic medicine.

Teleflex Medical OEM / Kohlberg & Company: The company entered into a definitive agreement to be acquired by Kohlberg & Company and Montagu Private Equity through a $1.5 billion LBO on December 9, 2025. The company is a manufacturer of medical-device components and interventional systems intended for use in diagnostic and therapeutic procedures.

Arthrosi Therapeutics / Swedish Orphan Biovitrum: The company reached a definitive agreement to be acquired by Swedish Orphan Biovitrum, a subsidiary of AstraZeneca, for up to $1.5 billion on December 13, 2025. The company is a developer of biotechnology drugs designed to reduce flare and tophi in gout patients.

Bluejay Therapeutics / Mirum Pharmaceuticals: The company reached a definitive agreement to be acquired by Mirum Pharmaceuticals for $820 million on December 8, 2025. The company is a developer of therapeutic medicines designed to provide curative treatments for serious viral and liver diseases.

Medical Manufacturing Technologies / Perimeter Solutions: The company entered into a definitive agreement to be acquired by Perimeter Solutions, via its financial sponsors Berkshire Partners, Meritage Funds, Tiger Global Management, Principal Global Investors, Select Equity Group, The WindAcre Partnership, Tiger Eye Capital, Eminence Capital, Janus Henderson Investors, and Matrix Capital Management, through a $685 million LBO on December 10, 2025. The company is a manufacturer of automated manufacturing equipment and precision tools for the medical device industry.

Adverum Biotechnologies / Eli Lilly: The company was acquired by Eli Lilly for up to $262 million on December 9, 2025. The company is a developer of gene therapies for prevalent ocular diseases including diabetic macular edema.

Alexza Pharmaceuticals / Lee’s Pharmaceutical Holdings: Lee’s Pharmaceutical Holdings reached a definitive agreement to acquire the Staccato One Breath Platform Technology of Alexza Pharmaceuticals for $15 million on December 9, 2025. The company is a developer of aerosol drug delivery platforms enabling rapid pulmonary administration of pharmaceuticals.

Applied Therapeutics / Cycle pharma: The company reached a definitive agreement to be acquired by Cycle pharma for an undisclosed amount on December 11, 2025. The company is a developer of novel therapeutics targeting validated molecular pathways in high unmet medical need indications.

iFocus Health / HarmonEyes: The company was acquired by HarmonEyes for an undisclosed amount on December 10, 2025. The company is a developer of digital health platforms measuring the effectiveness of ADHD treatments through objective assessments.

O.R. Trax / Banyan Software: The company was acquired by Banyan Software, via its financial sponsors Pacific Lake, Norwest, Rock Creek Capital, and Ares Management, through an LBO on December 8, 2025 for an undisclosed amount. The company is a developer of vendor and visitor credentialing software for healthcare facilities that excludes protected health information.

P1 Trials / Pratia: The company was acquired by Pratia, a subsidiary of Neuca, for an undisclosed amount on December 8, 2025. The company is a developer of clinical trial support services designed for early-phase oncology research purposes.

Safepath Laboratories / KVP International: The company was acquired by KVP International, via its financial sponsor Carmelina Capital Partners, through an LBO on December 12, 2025 for an undisclosed amount. The company is an operator of diagnostic laboratories specializing in rapid test development, research, and manufacturing for veterinary and human health.

Samarit Medical / PHS Group: The company was acquired by PHS Group for an undisclosed amount on December 12, 2025. The company is a manufacturer of patient handling and mobility products intended to serve healthcare facilities and home care markets.

Xanitos / Bessemer Investors: The company was acquired by Bessemer Investors through an LBO on December 9, 2025 for an undisclosed amount. The company is a provider of hospital support services including environmental services, patient transportation, and facility operations.

Protego Biopharma: The company raised $130 million of Series B venture funding in a deal led by Novartis Venture Fund and Forbion on December 1, 2025, putting the company’s pre-money valuation at $86.5 million. Scripps Research, MPM BioImpact, Lightspeed Venture Partners, Vida Ventures (Los Angeles), Omega Funds, Digitalis Ventures, YK Bioventures, Droia Ventures and other undisclosed investors also participated in the round. The company is a developer of small molecule therapeutics designed to reprogram protein folding for systemic amyloid and protein misfolding diseases.

TRIANA Biomedicines: The company raised $120 million of Series B venture funding in a deal led by Bessemer Venture Partners and Ascenta Capital on December 3, 2025, putting the company’s pre-money valuation at $138 million. Pfizer Ventures, Regeneron Ventures, The Invus Group, Finchley Healthcare Ventures, YK Bioventures, Atlas Venture, RA Capital Management, Lightspeed Venture Partners and Surveyor Capital also participated in the round. The company is a developer of molecular glue therapeutics for various disease indications.

Excelsior Sciences: The company raised $70 million of Series A venture funding in a deal led by Deerfield Management, Khosla Ventures and Sofinnova Partners on December 3, 2025, putting the company’s pre-money valuation at $26 million. Eli Lilly, Cornucopian Capital, Illinois Ventures, Massachusetts Institute of Technology, Empire State Development and other undisclosed investors also participated in the round. The company also received $25 million of grant funding from Empire State Development.  The company is an operator of a chemistry innovation platform providing machine-ready, automated, AI-driven small-molecule discovery and manufacturing.

Artera: The company raised $65 million of venture funding in a deal led by Lead Edge Capital on December 3, 2025. Summation Health Ventures, Heritage Medical Systems, Jackson Square Ventures, and Health Velocity Capital also participated in the round. The company is a developer of a patient communication platform designed to eliminate phone tags and improve the healthcare experience.

Xeltis: The company raised an estimated EUR 50 million of venture funding through a combination of debt and equity on December 2, 2025. An estimated EUR 12.5 million of venture funding was provided by EQT Life Sciences, Invest-NL and other undisclosed investors. An estimated EUR 37.5 million of debt was provided by European Investment Bank. The company is a developer of medical devices for restorative cardiovascular therapy.

Akura Medical: The company raised $53 million of Series C venture funding in a deal led by Qatar Investment Authority on December 1, 2025, putting the company’s pre-money valuation at $162 million. The company is a developer of medical devices for blood clot removal procedures.

SciNeuro Pharmaceuticals: The company raised $53 million of venture funding in a deal led by ARCH Venture Partners and Lilly Asia Ventures on December 4, 2025. The company is a developer of novel therapeutics for CNS diseases and neurological disorders.

Accession Therapeutics: The company raised GBP 30.5 million of venture funding from undisclosed investors on December 4, 2025. The company is a developer of targeted immuno-oncology therapeutics.

Aminex Therapeutics: The company raised $15 million of venture funding from undisclosed investors on December 4, 2025. The company is an operator of a drug development business advancing novel immunotherapies for cancer treatment.

Aether Bio: The company raised $15 million of Series A venture funding in a deal led by Tribe Capital on December 3, 2025, putting the company’s pre-money valuation at $95 million. Henkel Ventures, Radicle Impact, Shrug Capital, Natural Capital (US), Unless, Resilience Reserve, 4DX Ventures, and other undisclosed investors also participated in the round. The company is a developer of a biocatalyst engineering technology designed to repurpose enzymes for novel compound creation.

Curi Bio: The company raised $10 million of Series B venture funding in a deal led by Dream CIS on December 2, 2025, putting the company’s pre-money valuation at $52 million. The company is a developer of a human stem cell-based platform designed to facilitate the discovery of medicines by integrating human cells, systems, and data.

Portrai: The company raised KRW 14.5 billion of Series B venture funding from Pearl Abyss Capital, CKD Venture Capital, and Kakao Ventures on December 2, 2025. BNH Investment, BonAngels Venture Partners, Envisioning Partners, and Stic Alternative also participated in the round. The company is a developer of AI-enabled spatial transcriptomics platforms for enhanced biopsy analysis.

X9: The company raised $8.5 million of venture funding from undisclosed investors on December 5, 2025. The company is a developer of robotic medical imaging and procedural assistance technology intended for minimally invasive diagnostics and interventions.

SMi Systems: The company is in the process of raising GBP 5 million of venture funding on December 1, 2025, putting the company’s pre-money valuation at GBP 35 million. The company is a developer of single-molecule discovery and diagnostic tools designed for biomedical research and clinical diagnostics.

Prokarium: The company raised GBP 4.8 million of venture funding from Flerie on December 2, 2025. The company is an operator of a biopharmaceutical business intended for developing bacterial immunotherapies for cancer.

OYE Therapeutics: The company raised $5.6 million of venture funding in the form of convertible debt from undisclosed investors on December 5, 2025. The company is an operator of a clinical-stage pharmaceutical development business formulating clinical solutions from existing drugs.

Armonica Technologies: The company raised $4.2 million of venture funding from undisclosed investors on December 5, 2025. The company is a developer of long-read DNA sequencing platforms to sequence complete human genomes rapidly.

Bevimi: The company raised an undisclosed amount of venture funding from Able Partners in December 2025. The company is a developer of health and wellness solutions intended to address neuroinflammation and support cognitive performance.

Biocanic: The company raised an undisclosed amount of venture funding from Labcorp Venture Fund in December 2025. The company is a developer of a health intelligence platform designed to manage data-driven insights for health and wellness coaches.

CytoHub: The company raised an undisclosed amount of venture funding from Red Cedar Ventures in December 2025. The company is a developer of a cell biology research and development platform designed to support discovery and preclinical programs.

Eon Systems: The company raised an undisclosed amount of venture funding from Untapped Ventures and Reified in December 2025. The company is an operator of a neurotechnology business intended to emulate human-scale intelligence through fidelity brain mapping and digital reconstruction.

Tessera Therapeutics: The company is in the process of raising $150 million of venture funding from Regeneron Pharmaceuticals as of December 1, 2025. The company is a developer of gene writing technology for permanent genome alterations and modifications.

Alvogen Group / Lotus Pharmaceutical: The company was acquired by Lotus Pharmaceutical, a subsidiary of Alvogen Group, for $2 billion on December 3, 2025. The company is a manufacturer of specialty pharmaceutical, generic, and branded products for global markets.

ViceBio / Sanofi: The company was acquired by Sanofi for $1.6 billion on December 5, 2025. The company is a developer of vaccines designed for respiratory viral infections.

Foresight Diagnostics / Natera: The company was acquired by Natera for $275 million on December 5, 2025. The company is a developer of blood-based cancer detection diagnostics for early-stage identification.

Mural Oncology / Xoma: The company was acquired by Xoma for $36.2 million on December 5, 2025. The company is a clinical-stage oncology business whose activities are focused on discovering and developing immunotherapies for cancer patients.

Akros Pharma / Shionogi & Co.: The company, a subsidiary of Japan Tobacco was acquired by Shionogi & Co. for JPY 3.6 billion on December 1, 2025. The company is a developer of pharmaceutical products designed to treat various diseases.

Paradigm Spine / Companion Spine: The company, a subsidiary of Xtant Medical Holdings, was acquired by Companion Spine for $19.2 million on December 1, 2025. The company is a developer of non-fusion spinal implant technology.

Alerje / SemPresto: The Omniject Platform of Alerje, was acquired by SemPresto for an undisclosed amount on December 4, 2025. The company is a developer of a health technology solution intended for individuals with severe food allergies.

Freenome / Perceptive Capital Solutions: The company reached a definitive agreement to combine with Perceptive Capital Solutions through a reverse merger on December 05, 2025. The company is a developer of multi-omics platforms for early-stage cancer detection through routine blood draws.

POLYPOINT / Main Capital Partners: The company was acquired by Main Capital Partners through an LBO on December 4, 2025 for an undisclosed amount. The company is a developer of workforce management software designed to support staff participation, flexible scheduling and performance coordination.

Winback / Charterhouse Capital Partners: The company was acquired by Charterhouse Capital Partners and its management through an LBO on December 2, 2025 for an undisclosed amount. The company is a developer of medical devices intended for therapeutic applications.

YourBio Health / Hims & Hers Health: The company reached a definitive agreement to be acquired by Hims & Hers Health for an undisclosed amount on December 3, 2025. The company is a developer of a bladeless blood collection device.

Ablative Solutions: The company raised $76.9 million of Series 2 venture funding from undisclosed investors on November 26, 2025. The company is a developer of catheter-based neurolytic delivery systems designed for therapeutic intervention in hypertension.

Quarry Thera: The company raised $32 million of Series A venture funding from Eli Lilly, Yosemite and Canaan Partners on November 24, 2025. F-Prime Capital also participated in the round. The company is a developer of proximity-driven therapeutics designed to overcome limitations in conventional drug modalities.

Dayra Therapeutics: The company raised $20 million of venture funding from Versant Ventures on November 24, 2025. The company is a developer of oral macrocyclic peptide therapeutics for treating serious diseases with improved bioavailability and target selectivity.

Luminate Medical: The company raised $17.5 million of Series A venture funding in a deal led by 8VC, Atlantic Bridge Capital and ARTIS Ventures on November 24, 2025, putting the company’s pre-money valuation at $19.5 million. SciFounders, Faber Ventures, Metaplanet Holdings, Calm Ventures, Finn Murphy, Steve Pacelli and Lachy Groom also participated in the round. The company is a developer of medical devices for improving cancer treatment delivery and patient outcomes.

MindImmune: The company raised $16.3 million of Series A venture funding from Pfizer Ventures and other undisclosed investors on November 24, 2025, putting the company’s pre-money valuation at $27.15 million. The company is a developer of antibody-based therapeutics targeting central nervous system diseases including neurodegenerative disorders.

Neela Therapeutics: The company raised $12 million of venture funding in the form of convertible debt from Biogen on November 24, 2025. The company is a developer of gene therapies for treating rare pediatric neurogenetic diseases and central nervous system disorders.

BTB Therapeutics: The company raised $6.7 million of venture funding from undisclosed investors on November 30, 2025. The company is a developer of small-molecule RNA splicing modulators for non-opioid pain management and cancer immunotherapy applications.

Sunflower: The company raised $6 million of venture funding in a deal led by Flybridge on November 28, 2025, putting the company’s pre-money valuation at $54 million. Y Combinator, Gaingels and other undisclosed investors also participated in the round. The company is a developer of digital addiction recovery platforms providing behavioral therapy and support for substance use disorders.

Huxley Medical: The company raised $5.9 million of venture funding from undisclosed investors on November 26, 2025. The company is a developer of flexible telehealth platforms providing continuity of care across multiple healthcare settings and locations.

Morphle: The company raised $5 million of Series A venture funding led by Inflexor on November 25, 2025. The company is a developer of an online pathology scanner designed to facilitate pathologists in collaborating with other doctors in real time.

Aurora Cold Plasma Sterilisation: The company raised EUR 3.8 million of venture funding through a combination of debt and equity from Normandie Participations, GO Capital and European Innovation Council on November 27, 2025. The company is a developer of room-temperature plasma sterilization systems for processing heat-sensitive and complex medical devices.

NanoMosaic: The company raised $4 million of venture funding from undisclosed investors on November 24, 2025. The company is a developer of a nanoneedle proteomic beta system designed to assist in proteomics.

BC3 Technologies: The company raised $3.6 million of Series A funding from undisclosed investors on November 26, 2025, putting the company’s pre-money valuation at $36.8 million. The company is a developer of chitosan-based aerosolized hemostatic products for rapid hemorrhage control in emergency and surgical settings.

Axo Longevity: The company raised an undisclosed amount of venture funding from 51Ventures on November 25, 2025. The company is a provider of clinical laboratory testing services designed for the diagnosis and monitoring of autoimmune, hematologic, metabolic, and cardiovascular conditions.

MiCare Path: The company raised Series C and D venture funding on November 25, 2025. The company is a developer of virtual care navigation platforms for coordinating patient care pathways.

Abyrx / MedEdge Holdings: The company was acquired by MedEdge Holdings as a part of a $450 million deal on November 24, 2025. The company is a developer of surgical therapeutic devices for improving procedural efficiency and patient outcomes.

DB Orthodontics / Lifco: The company reached a definitive agreement to be acquired by Lifco, a subsidiary of Carl Bennet, for an undisclosed amount on November 25, 2025. The company is a manufacturer of orthodontic products including clear aligners, archwires, bands, and bracket attachments.

Liora Technologies Europe / Lixte Biotechnology Holdings: The company was acquired by Lixte Biotechnology Holdings for an undisclosed amount on November 25, 2025. The company is a manufacturer of electronically controlled proton beam therapy systems for treating various cancer types.

NeuWave Medical / Quantum Surgical: The company was acquired by Quantum Surgical for an undisclosed amount on November 26, 2025. The company is a developer of energy-based minimally invasive surgical devices including microwave ablation systems in Madison, Wisconsin.

North Bay Prosthetics / Lagarrigue: The company was acquired by Lagarrigue, via its financial sponsors Eurazeo, Grand Sud Ouest Capital, Halisol Groupe, IDIA Capital Investissement, Multicroissance, Naxicap Partners and RAISE Group, through an LBO on November 27, 2025 for an undisclosed amount. The company is a provider of custom prosthetic limbs and orthotic devices for rehabilitation and mobility restoration.

SparxConnect / FluidAI: The company was acquired by FluidAI for an undisclosed amount on November 26, 2025. The company is a developer of patient engagement and communication platforms for facilitating person-centered healthcare delivery.

Solve Therapeutics: The company raised $321 million of Series A venture funding in a deal led by Yosemite on November 17, 2025, putting the company’s pre-money valuation at $118 million. Merck & Co., Ally Bridge Group, General Atlantic, Decheng Capital, Abingworth, Alexandria Venture Investments, DC Ventures, SymBiosis, Balyasny Asset Management, B Capital, Matrix Capital Management, Surveyor Capital, and other undisclosed investors also participated in the round. The company is an operator of a biotechnology platform intended to develop novel antibody-drug conjugates.

Artios: The company raised $115 million of Series D venture funding in a deal led by SV Health Investors and RA Capital Management on November 17, 2025. M Ventures, Novartis Venture Fund, Pfizer Ventures, Andera Partners, The Invus Group, Sofinnova Partners, EQT Life Sciences, IP Group, Omega Funds, Piper Heartland, Schroders Capital, Janus Henderson Investors and Avidity Partners also participated in the round. The company is a developer of novel cancer treatments designed to target deoxyribonucleic acid (DNA) damage response.

Aspen Neuroscience: The company raised $115 million of Series C venture funding in a deal led by OrbiMed, ARCH Venture Partners and Revelation Partners on November 20, 2025, putting the company’s pre-money valuation at $231 million. Kite Pharma, Cormorant Asset Management, LYFE Capital, Lifeforce Capital, Axon Ventures, S32, Medical Excellence Capital, Prebys Ventures, Balyasny Asset Management, and other undisclosed investors also participated in the round. The company is a developer of autologous cell therapies and personalized medicines designed for a broad spectrum of diseases, including Parkinson’s disease.

Profluent: The company raised $106 million of Series B venture funding in a deal led by Altimeter Capital Management and Bezos Expeditions on November 19, 2025, putting the company’s pre-money valuation at $419 million. Insight Partners, Air Street Capital, Spark Capital and other undisclosed investors also participated in the round. The company is a developer of artificial intelligence-driven models designed to create and validate novel proteins for biomedicine.

Eight Sleep: The company raised $99.1 million in Series D venture funding in a deal led by Valor Equity Partners, Hongshan Capital Group and Founders Fund on November 18, 2025, putting the company’s pre-money valuation at $1.4 billion. Zak Brown, Charles Leclerc and other undisclosed investors also participated in the round. The company is an operator of a sleep product brand intended to improve and support optimal rest, health, and daily function.

Freenome: The company raised $75 million of venture funding from Roche and other undisclosed investors on November 17, 2025. The company is a developer of a multi-omics platform designed to detect cancer at an early stage through a routine blood sample.

Lifordi Immunotherapeutics: The company raised $42 million of venture funding from Sanofi, 5AM Ventures and Atlas Venture on November 18, 2025. ARCH Venture Partners also participated in the round. The company is a developer of targeted antibody-drug conjugates (ADCs) designed to treat autoimmune and inflammatory disorders.

Bambusa Therapeutics: The company raised an estimated $40 million of Series A2 venture funding from Dawn Biopharma, Redmile Group and The Invus Group on November 17, 2025, putting the company’s pre-money valuation at $515 million. INCE Capital, RA Capital Management, Janus Henderson Investors, Salvia (Holzkirchen), ADAR1 Capital Management, Athos (Family Office), BVF Partners, and other undisclosed investors also participated in the round. The company is an operator of a biotechnology business intended to create bispecific antibodies for treating immunological and inflammatory disorders.

Angiex: The company raised $31 million of venture funding in a deal led by Paulson Investment Company on November 17, 2025. The company is a developer of vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis.

VasoRx: The company raised $28.9 million of venture funding from undisclosed investors on November 17, 2025. The company is a developer of RNA (Ribonucleic acid) therapies intended to treat diseases of the cardiovascular system, as well as oncology.

Arpeggio: The company raised $24 million of venture funding in a deal led by Builders Fund on November 19, 2025, putting the company’s pre-money valuation at $49 million. Ms2 Capital and other undisclosed investors also participated in the round. The company is a developer of a drug assessment technology designed to study mechanistic understanding of how drugs work.

VahatiCor: The company raised $23 million in Series B venture funding in a deal led by S3 Ventures on November 18, 2025, putting the company’s pre-money valuation at $25 million. Intuitive Surgical, and other undisclosed investors also participated in the round. The company is a developer of a medical technology platform designed to alleviate angina for patients who have exhausted current medical therapies.

Solarea Bio: The company raised $9.9 million in Series B venture funding from undisclosed investors on November 19, 2025, putting the company’s pre-money valuation at $27 million. The company is a developer of microbiome-based therapeutics designed to improve human health.

Spineology: The company received $8.7 million of development capital from undisclosed investors on November 19, 2025. The company is a developer of spinal implants designed to provide relief for patients suffering from spinal cord pain.

Skeletalis: The company raised $8 million of venture funding in a deal led by Pillar VC on November 17, 2025. Slocum Management, KdT Ventures and Age 1 also participated in the round. The company is a developer of a targeted small-molecule delivery system designed for improving skeletal health.

Lumia Health: The company raised $7 million of venture funding in a deal led by J2 Ventures on November 20, 2025. BonAngels Venture Partners and other undisclosed investors also participated in the round. The company is a developer of a wearable medical device designed for continuous blood flow tracking in patients with chronic neurological and cardiovascular conditions.

Adze Biotechnology: The company raised $6.2 million of Series A venture funding from undisclosed investors on November 17, 2025. The company is a developer of oncologic immunotherapies designed to help in the treatment of cancers with significant unmet needs.

General Control: The company raised $5.5 million of venture funding from Age 1 and Fifty Years on November 17, 2025. The company is a developer of multiplexed epigenetic medicines designed to address the complexity of age-related diseases.

American Gene Technologies: The company is in the process of raising venture funding on November 18, 2025. The company is a developer of gene and cell therapy designed to cure infectious diseases, cancers, and inherited disorders.

OrPro Therapeutics: The company is in the process of raising venture funding in the form of SAFE notes on November 20, 2025. The company is an operator of a biologic drug platform intended to protect cells from inflammatory and oxidative stress-related damage.

SeraGene Therapeutics: The company raised an undisclosed amount of venture funding from Boxer Capital, Foresite Capital and Commodore Capital on November 20, 2025. Deep Track Capital, Pathway to Cures, Adage Capital Management, Blue Owl Capital, and Logos Capital also participated in the round. The company is a developer of ribonucleic acid-based therapeutics designed to provide long-lasting control over coagulation disorders.

Exact Sciences / Abbott: The company reached a definitive agreement to be acquired by Abbott for $23.5 billion on November 20, 2025. Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally.

Halda Therapeutics / Johnson & Johnson: The company reached a definitive agreement to be acquired by Johnson & Johnson for $3 billion on November 17, 2025. The company is a developer of a drug discovery platform designed to create therapeutic and precision medicines.

Intelerad Medical Systems / GE HealthCare Technologies: The company reached a definitive agreement to be acquired by GE HealthCare Technologies for an estimated $2.3 billion as of November 19, 2025. The company is a developer of a medical imaging platform intended for clinicians and global healthcare organizations.

Elektrofi / Halozyme Therapeutics: The company was acquired by Halozyme Therapeutics for $900 million on November 18, 2025. The company is a developer of a drug delivery platform designed to enhance subcutaneous administration.

Acera Surgical / Solventum: The company reached a definitive agreement to be acquired by Solventum for $725 million on November 20, 2025. The company is a manufacturer of synthetic biomaterials intended to support soft tissue repair and regenerative medicine across surgical specialties.

Surmodics / GTCR: The company was acquired by GTCR through a $627 million public-to-private LBO on November 19, 2025. Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays.

Aptose Biosciences / HS North America: The company reached a definitive agreement to be acquired by HS North America, a subsidiary of Hanmi Pharm for an undisclosed amount amount on November 19, 2025. Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology.

Capsugel / Multiple Investors: The company, a subsidiary of Lonza Group, has received bids to be acquired by Lone Star Funds, Altaris and One Rock Capital Partners through an LBO as of November 19, 2025 for an undisclosed amount. The company is a developer and manufacturer of capsules based in Morristown, New Jersey.

Clinetic / MRO: The company was acquired by MRO, via its financial sponsors Healthworx and Parthenon Capital Partners, through an LBO on November 18, 2025 for an undisclosed amount. The company is a provider of enterprise software designed for clinical trial recruitment optimization.

Injectech / Vance Street Capital: The company, a subsidiary of The West Group, was acquired by Vance Street Capital through an LBO on November 19, 2025 for an undisclosed amount. The company is a manufacturer of precision injection molding and cleanroom assembly intended for medical device, life science, and bioprocessing markets.

MedNet / CRScube: The company was acquired by CRScube for an undisclosed amount on November 18, 2025. The company is a developer of a cloud-based clinical data management system designed to help sponsors achieve their clinical research goals.

Melt Pharmaceuticals / Harrow: The company was acquired by Harrow for an undisclosed amount on November 18, 2025. The company is a developer of non-intravenous and non-opioid sedation and analgesia medicines designed for short-duration medical procedures in outpatient and in-office settings.

Molzym / Bruker: The company was acquired by Bruker for an undisclosed amount on November 19, 2025. The company is a manufacturer of amplification reagents and diagnosis kits designed for microbial nucleic acid extraction from a variety of specimens.

P95 / Ampersand Capital Partners: The company was acquired by Julius Clinical Research and Ampersand Capital Partners through an LBO on November 19, 2025 for an undisclosed amount. The company is a provider of epidemiology and clinical research services intended for the pharmaceutical industry.

Peak Analysis and Automation / Grenova: The company was acquired by Grenova, via its financial sponsors Peloton Equity, Stonehaven Capital, Morgan Stanley and Hamilton Lane, through an LBO on November 18, 2025 for an undisclosed amount. The company is a manufacturer of a comprehensive range of laboratory workcells and advanced robotic systems designed to streamline and automate complex laboratory workflows across various applications.

SUN bioscience / InSphero: The company was acquired by InSphero for an undisclosed amount on November 17, 2025. The company is a developer of a drug culture platform designed to deliver personalized medicine through patient-specific organoids.

TotallBody.com / Med Holdings Group: The company was acquired by Med Holdings Group for an undisclosed amount on November 19, 2025. The company is a developer of a telehealth and longevity medicine platform designed to deliver comprehensive wellness, weight loss, hormone therapy, and medicine programs to patients worldwide.

Iambic: The company raised $100 million of Series B venture funding from EverBright, Regeneron Ventures and Wilson Sonsini Goodrich & Rosati on November 10, 2025, putting the company’s pre-money valuation at $449.5 million. Terra Magnum Capital Partners, Alexandria Venture Investments, Pegasus Tech Ventures, ARK Ventures (US), Freeflow Ventures, Catalio Capital Management, Sequoia Capital, Tao Capital Partners, Ascenta Capital, Abingworth, Illumina Ventures, Alumni Ventures, Qatar Investment Authority, Mubadala Capital and other undisclosed investors also participated in the round. The company is a developer of artificial intelligence-powered computational drug design platforms for optimizing small molecule therapeutics and addressing complex drug discovery challenges.

T-Therapeutics: The company raised $91 million of Series A venture funding in a deal led by Digitalis Ventures, Cambridge Innovation Capital, and F-Prime Capital on November 13, 2025. Tencent Holdings, Sanofi Ventures, BGF, and Cambridge Enterprise Ventures also participated in the round. The company is a developer of engineered soluble biologic therapeutics for treating oncology and immunological diseases.

Gate Bioscience: The company raised $65 million of Series B venture funding in a deal led by Forbion on November 13, 2025, putting the company’s pre-money valuation at $96 million. GV, Eli Lilly, Andreessen Horowitz, Versant Ventures, ARCH Venture Partners, and other undisclosed investors also participated in the round. The company is a developer of small molecule drugs that selectively degrade extracellular proteins within cells to prevent disease-causing protein secretion.

4TEEN4 Pharmaceuticals: The company raised EUR 55 million of Series C venture funding from undisclosed investors on November 13, 2025. The company is a developer of precision medicine designed to improve outcomes in critical care for acute cardiovascular complications.

House Rx: The company raised $55 million of Series B venture funding in a deal led by New Enterprise Associates and Town Hall Ventures on November 12, 2025. Silicon Valley Bank, Bessemer Venture Partners, LRVHealth, and First Round Capital also participated in the round. The company is an operator of a technology-enabled specialty pharmacy providing home delivery and patient support services for complex medications.

Clairity: The company raised $43 million of Series B venture funding from Breast Cancer Research Foundation, Santé Ventures, and ACE GESTAO GLOBAL on November 13, 2025. The company is a developer of a mammography-based deep-learning platform designed for early breast cancer detection.

Saluda Medical: The company received $30 million of development capital from undisclosed investors on November 12, 2025. The company is a developer of closed-loop neuron modulation devices intended to treat chronic neuropathic pain.

Pinteon Therapeutics: The company raised $29.2 million of Series B venture funding from undisclosed investors on November 12, 2025. The company is a developer of antibody therapeutics targeting neuroinflammation and neurodegenerative pathways to preserve brain health.

myTomorrows: The company raised EUR 25 million of venture funding from Avego Management on November 11, 2025. The company is an operator of a healthcare platform connecting patients with investigational treatments and expanded access programs for drugs in clinical development.

Aureka Biotechnologies: The company raised $23.2 million of Series A venture funding in a deal led by Qiming Venture Partners and 5Y Capital on November 10, 2025. Agentic Ventures and Newley Capital also participated in the round. The company is a developer of computational therapeutic discovery platforms using artificial intelligence for large-scale drug design automation.

Indivi: The company raised CHF 15 million of venture funding in a deal led by Ava Investors and other undisclosed investors on November 12, 2025, putting the company’s pre-money valuation at CHF 126 million. The company is a developer of digital biomarkers and wearable sensing technology for monitoring neurological conditions and supporting neuroscience drug development.

Virometix: The company raised $15 million of venture funding from undisclosed investors on November 13, 2025. The company is a developer of vaccines and immunotherapeutic drugs designed to prevent and treat infections and chronic human diseases.

ZetaGen Therapeutics: The company received $12.9 million of development capital from undisclosed investors on November 12, 2025. The company is a developer of a small molecule-based osteoinductive technology designed to suspend cancer, inhibit pain and regenerate bone.

Elixirgen Therapeutics: The company raised $8.2 million of venture funding in the form of convertible debt from undisclosed investors on November 13, 2025. The company is a developer of stem cell therapies and regenerative medicine approaches for treating neurodegenerative diseases including Alzheimer’s disease.

Ladder Bio: The company raised $5.5 million of venture funding in a deal led by Medical Excellence Capital on November 12, 2025. Hatch Biofund Management also participated in the round. The company is a developer of computational chemistry platforms for designing spiroligomers and synthetic molecular structures for therapeutic applications.

Micro Medical Solutions: The company raised $4.7 million of venture funding from undisclosed investors on November 13, 2025. The company is a developer of microvascular intervention devices and therapies for preventing limb amputations in patients with peripheral artery disease.

Alume Biosciences: The company raised $3.6 million of Series C venture funding from undisclosed investors on November 11, 2025. The company is a developer of fluorescence imaging technology that illuminates nerve tissue during surgical procedures to enable nerve-sparing precision surgery.

Model Medicines: The company raised $3.2 million of venture funding from undisclosed investors on November 13, 2025. The company is a developer of artificial intelligence-powered drug discovery platforms for accelerating therapeutic development.

iRiva Medical: The company raised an undisclosed amount of venture funding in a deal led by F-Prime Capital on November 11, 2025. Hatteras Venture Partners, Norwest and Treo Ventures also participated in the round. The company is a developer of implantable neuromodulation devices for treating chronic pain and other persistent health conditions.

Kiyatec: The company raised an undisclosed amount of venture funding in a deal led by Medical & Bio Decision on November 14, 2025. The company is a developer of three-dimensional cell culture technology for predicting patient-specific therapeutic responses before initiating treatment.

Leukogene Therapeutics: The company raised an undisclosed amount of venture funding from SC Launch and South Carolina Research Authority on November 12, 2025. The company is an operator of an oncology-focused biotech business intended to accelerate the development of new therapeutics for patients with advanced-stage cancer.

Vascarta: The company is in the process of raising Series A venture funding on November 10, 2025. The company is a developer of pharmaceutical drug candidates and novel delivery systems for treating chronic inflammatory diseases and certain cancer types.

Cidara Therapeutics / Merck & Co.: The company reached a definitive agreement to be acquired by Merck & Co. for $9.2 billion on November 14, 2025. Cidara Therapeutics Inc develops immunotherapeutic conjugates and antiviral drugs for treating serious infectious diseases and immune disorders.

Mersana Therapeutics / Day One Biopharmaceuticals: The company reached a definitive agreement to be acquired by Day One Biopharmaceuticals for up to $285 million on November 13, 2025. Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company developing antibody-drug conjugates for treating solid tumors and hematological cancers with unmet medical needs.

Crown Bioscience / Adicon Clinical Laboratory: The company, a subsidiary of JSR, reached a definitive agreement to be acquired by Adicon Clinical Laboratory for $204 million on November 13, 2025. The company is an operator of a contract research organization providing preclinical oncology services, drug discovery support, and translational research for biopharmaceutical development.

Alcyone Therapeutics / Biogen: The company was acquired by Biogen for an undisclosed amount on November 14, 2025. The company is a developer of intrathecal drug delivery systems and catheter-based technologies for delivering therapeutics directly to the central nervous system.

CIMAR / DeepHealth: The company was acquired by DeepHealth, a subsidiary of RadNet, for an undisclosed amount on November 11, 2025. The company is a developer of cloud-based medical imaging and health information exchange platforms enabling secure data sharing among healthcare providers.

Cisteo Medical / Agon Electronics: The company was acquired by Agon Electronics, via its financial sponsor Argos Fund, through an LBO on November 13, 2025 for an undisclosed amount. The company is a manufacturer of medical devices and provides contract assembly services for healthcare product development and commercialization.

Doppl / InSphero: The company reached a definitive agreement to be acquired by InSphero for an undisclosed amount on November 11, 2025. The company is a developer of three-dimensional biological modeling systems and organoid technologies for preclinical drug testing and therapeutic development..

Repare Therapeutics / XenoTherapeutics: The company reached a definitive agreement to be acquired by XenoTherapeutics for $78.2 million on November 15, 2025. Repare Therapeutics Inc is a precision oncology company developing synthetic lethality-based cancer therapeutics targeting DNA damage repair pathways.

Swixx Biopharma / Multiple Investors: The company has received bids to be acquired by Lone Star, SK Capital Partners and DKSH Holding through an LBO as of November 16, 2025 for an undisclosed amount. The company is a provider of pharmaceutical commercialization and market access services including sales, marketing, and distribution for biopharmaceutical, over-the-counter, and medical device companies.

Tonic Health / Luma Health: The company was acquired by Luma Health for an undisclosed amount on November 12, 2025. The company is an operator of a patient data collection and payment processing platform for gathering health information and managing financial transactions across multiple devices.

Synchron: The company raised $200 million of Series D venture funding in a deal led by Double Point Ventures on November 6, 2025. Protocol Labs, IQTalent Partners, Qatar Holding, K5 Global, XEIA Venture Partners, In-Q-Tel, T.Rx Capital, Metis Innovative, Khosla Ventures, ARCH Venture Partners, NewTech Invest, National Reconstruction Fund Corporation, Bezos Expeditions and Qatar Investment Authority also participated in the round. The company is a developer of implantable brain-computer interface devices using endovascular stent-electrode arrays that enable neural signal recording and control for paralyzed patients.

Braveheart Bio: The company raised $185 million of Series A venture funding in a deal led by OrbiMed, Forbion and Andreessen Horowitz on November 5, 2025. Enavate Sciences and Frazier Healthcare Partners also participated in the round. The company is a developer of a cardiac myosin inhibitor intended for treating cardiovascular disorders.

Hippocratic AI: The company raised $126 million of Series C venture funding in a deal led by Avenir Growth Capital on November 3, 2025, putting the company’s pre-money valuation at $3.37 billion. Universal Health Services, WellSpan Health, Premji Invest, CapitalG, General Catalyst, Andreessen Horowitz, Cincinnati Children’s Hospital Medical Center, Kleiner Perkins, John Doerr, Rick Klausner, and other undisclosed investors also participated in the round. The company is a developer of artificial intelligence-powered virtual healthcare assistants and conversational agents for patient communication, triage, and care coordination.

Tempero Bio: The company raised $76.9 million of Series B venture funding in a deal led by 8VC on November 5, 2025, putting the company’s pre-money valuation at $71 million. Aditum Bio, Khosla Ventures, Palo Santo, SymBiosis and other undisclosed investors also participated in the round. The company is a developer of therapeutics for treating and preventing substance use disorders including alcohol and opioid addiction.

Neok Bio: The company raised $75 million of Series A venture funding from ABL Bio and other undisclosed investors on November 4, 2025, putting the company’s pre-money valuation at $41.5 million. The company is a developer of oncology therapeutics and cancer immunotherapies targeting novel biological pathways to improve treatment efficacy and patient outcomes.

Sovato: The company raised $26 million of Series B venture funding in a deal led by Beringea on November 4, 2025. GS Ventures (Korea), Teladoc Health, Polaris Partners, Puma Venture Capital and Laerdal Million Lives Fund also participated in the round. The company is a developer of a comprehensive telesurgery platform designed to make remote surgery and procedural programs safe, scalable, and commercially viable for healthcare organizations.

Onchilles Pharma: The company raised $25 million of Series A venture funding from LYZZ Capital, InVivium Capital, and Kennedy Lewis Investment Management on November 7, 2025. Lincoln Park Capital, The University of Chicago Office of Investments, and other undisclosed investors also participated in the round. The company is a developer of myeloid-targeted cancer immunotherapies and novel oncology therapeutics for treating solid tumors.

VisCardia: The company raised $20.9 million of Series C venture funding from undisclosed investors on November 3, 2025, putting the company’s pre-money valuation at $161 million. The company is a developer of implantable cardiac support devices for treating heart failure and thoracic cardiovascular diseases.

Dragon Vascular: The company raised $18.9 million of Series A venture funding from undisclosed investors on November 3, 2025, putting the company’s pre-money valuation at $17.1 million. The company is a developer of endovascular medical devices and catheter-based interventions for treating neurovascular disorders and peripheral vascular diseases.

Osteal Therapeutics: The company raised $15.6 million of Series E venture funding from undisclosed investors on November 5, 2025, putting the company’s pre-money valuation at $560 million. The company is a developer of infection therapeutics designed to reduce the mortality, morbidity, and cost of care associated with musculoskeletal infections.

Microplate Dx: The company is in the process of raising GBP 10 million of venture funding on November 6, 2025. The company is a developer of a medical diagnostic device designed to reduce deaths from drug-resistant infections.

Coherence: The company raised $10 million of venture funding in a deal led by Artesian on November 4, 2025. Spacewalk VC, Blackbird Ventures, Possible Ventures, XEIA Venture Partners, Jumpspace Ventures and Topology Ventures also participated in the round. The company is a developer of minimally invasive medical implants and devices for treating chronic medical conditions.

Olli Health: The company raised $10 million of Series A venture funding in a deal led by Industry Ventures on November 3, 2025. Tau Ventures, Arkitekt Ventures, Cannage Capital, and Equitage Ventures also participated in the round. The company is a developer of artificial intelligence-powered medical coding and documentation software for home healthcare agencies and visiting nurse services.

Auxira Health: The company raised $7.8 million of venture funding from Abundant Venture Partners and other undisclosed investors on November 4, 2025. The company is a provider of virtual clinical support services including remote scribing, care coordination, and administrative assistance for medical practices.

Epalex: The company raised $5.2 million of Series B venture funding from undisclosed investors on November 9, 2025. The company is a developer of pharmaceutical therapeutics for neurological disorders and central nervous system conditions.

Bayou Surgical: The company raised $5 million of Series B venture funding from undisclosed investors on November 5, 2025, putting the company’s pre-money valuation at $24 million. The company is a developer of surgical instruments and devices for minimally invasive laparoscopic and robotic surgery procedures.

Nymbl Systems: The company raised $4 million of venture funding from undisclosed investors on November 3, 2025. The company is a developer of electronic health records and practice management software for orthotics and prosthetics providers.

Implant Preservation Devices: The company raised $3.8 million of Series 1 venture funding from undisclosed investors on November 4, 2025. The company is a developer of medical devices for preventing and treating prosthetic joint infections and fracture-related infections.

Metsera / Pfizer: The company was acquired by Pfizer for $10 billion on November 8, 2025. Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions.

Parse Biosciences / Qiagen: The company reached a definitive agreement to be acquired by Qiagen for an estimated $225 million on November 4, 2025. The company is a developer of single-cell RNA sequencing technology and combinatorial barcoding platforms for high-throughput genomic analysis without specialized instrumentation.

Baergic Bio / Axsome Therapeutics: Axsome Therapeutics reached a definitive agreement to acquire the company, a subsidiary of Avenue Therapeutics, for an estimated $81.8 million on November 6, 2025. The company is a developer of neurological therapeutics for treating epilepsy and seizure disorders.

Evoke Pharma / QOL Medical: The company reached a definitive agreement to be acquired by QOL Medical on November 4, 2025. Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases.

BioMedomics / Orasure Technologies: The company reached a definitive agreement to be acquired by Orasure Technologies for an undisclosed amount on November 5, 2025. The company is a developer of point-of-care diagnostic tests and rapid testing devices for infectious diseases and cardiac biomarkers.

DNAsimple / Joined Bio: The company was acquired by Joined Bio for an undisclosed amount on November 3, 2025. The company is a provider of DNA sample collection kits and genomic research services for clinical studies and genomics laboratories.

Firstline Clinical / DoseMe: The company was acquired by DoseMe, a subsidiary of Fairlong Capital, for an undisclosed amount on November 3, 2025. The company is a developer of a healthcare technology platform intended to provide clinical guidelines for infectious diseases.

icometrix / GE HealthCare Technologies: The company was acquired by GE HealthCare Technologies for an undisclosed amount on November 7, 2025. The company is a developer of artificial intelligence-based software designed for the analysis of brain magnetic resonance imaging images.

L2P Research / NJ Bio: The company was acquired by NJ Bio, a subsidiary of Cohance, for an undisclosed amount on November 6, 2025. The company is an operator of a clinical research and development company intended to offer preclinical, oncology and toxicology services.

Parks Medical Electronics / Vascular Technology: The company was acquired by Vascular Technology, via its financial sponsor JLL Partners, through an LBO on November 5, 2025 for an undisclosed amount. The company is a manufacturer of doppler ultrasound devices and vascular diagnostic equipment for detecting blood flow abnormalities and cardiovascular conditions.

PhantomX / Ion Beam Applications: The company was acquired by Ion Beam Applications for an undisclosed amount on November 3, 2025. The company is a developer of medical-imaging technology and validation services intended to serve the clinical imaging, radiology research, and artificial intelligence sectors.

Plas-Tech Engineering / Presspart Verwaltungs: The company reached a definitive agreement to be acquired by Presspart Verwaltungs, a subsidiary of GEMI Grundstücksbesitz und verwaltungs, for an undisclosed amount on November 4, 2025. The company is a manufacturer of prefillable syringes, drug delivery devices, and medical device components for pharmaceutical and biotechnology companies.

studyOS / Sitero: The company was acquired by Sitero for an undisclosed amount on November 3, 2025. The company is a developer of an AI-enabled clinical data management platform intended to identify and relate risks between endpoint data, safety data, and overall reliability.

Techfit Digital Surgery / Acumed: The company was acquired by Acumed, a subsidiary of Medhold Group, for an undisclosed amount on November 5, 2025. The company is a developer of a digital surgery platform designed to enhance surgical planning and patient outcomes through workflow digitization and customization.

Tubulis: The company raised EUR 344 million of Series C venture funding in a deal led by Venrock on October 30, 2025. Andera Partners, Frazier Healthcare Partners, Blackstone, Ascenta Capital, Fund+, EQT Life Sciences, Nextech Invest, Deep Track Capital, High-Tech Gründerfonds, Seventure Partners, Bayern Kapital, OCCIDENT, Fidelity Management & Research Company, Janus Henderson Investors, Wellington Management and other undisclosed investors also participated in the round. The company is a developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases.

SetPoint Medical: The company raised $115 million of Series D venture funding in a deal led by Elevage Medical Technologies and Ally Bridge Group on October 28, 2025, putting the company’s pre-money valuation at $368 million. Northwell Health, Abbott, Norwest, Sprig Equity, and other undisclosed investors also participated in the round. The company is a developer of an implantable bioelectronic medical device designed to modulate neuroimmune pathways for reducing inflammation and restoring immunologic balance in chronic autoimmune conditions.

FLEX Vessel Prep: The company raised $49.2 million of Series C venture funding in a deal led by S3 Ventures on October 29, 2025, putting the company’s pre-money valuation at $11 million. Endeavour Vision, RiverVest Venture Partners, and other undisclosed investors also participated in the round. The company is a developer of endovascular medical devices intended to address unmet needs in treating peripheral arterial diseases.

Curve Biosciences: The company raised $40 million of venture funding in a deal led by Luma Group on October 29, 2025. Techas Capital, Civilization Ventures, LifeX Ventures, NZVC, Incite Ventures (San Francisco), First Spark Ventures, Mintaka VC Management and Micah Spear also participated in the round. The company is a developer of liver cancer diagnostics designed for disease prevention and screening.

Indomo: The company raised $25 million of venture funding from Atomic, Foresite Capital, and Polaris Partners on October 29, 2025. The company is a clinical-stage therapeutics business focused on developing at-home, self-administered treatments for inflammatory skin conditions like acne, with its lead product being the ClearPen, an intradermal auto-injector.

Stethophone: The company raised $10 million of venture funding in a deal led by Killick Capital and Klister Credit on October 29, 2025. Labrador Resources, Pelorus Venture Capital, Newfoundland Capital Management, and Brinex Capital also participated in the round. The company is a developer of a smartphone stethoscope designed to collect and collaborate on medical-grade cardiac and pulmonary data.

Primaa: The company raised EUR 7 million of Series A venture funding from SWEN Capital Partners, Super Capital and other undisclosed investors on October 29, 2025. The company is a developer of a medical diagnostic software designed for automated and accurate histological diagnoses.

Semalytix: The company raised EUR 5.7 million of venture funding in a deal led by Holland Capital on October 29, 2025. Other undisclosed investors also participated in the round. The company is a developer of artificial intelligence-powered analytics platforms that extract and analyze patient-reported experiences and real-world evidence from online health communities for oncology, inflammatory diseases, metabolic disorders, and respiratory conditions.

Avicenna Biosciences: The company raised $5.9 million of venture funding from DCVC Bio and other undisclosed investors on October 28, 2025. The company is a developer of machine learning-powered medicinal chemistry platforms for computational drug design and molecular optimization.

Alume Biosciences: The company raised $3 million of Series C venture funding from undisclosed investors on October 30, 2025. The company is a developer of a nerve illumination technology designed to help doctors perform precision surgery.

Terra Bioforge: The company is in the process of raising venture funding on October 31, 2025. The company is an operator of a a synthetic biology platform for discovering, engineering, and manufacturing bioactive natural products and therapeutic compounds for human, agricultural, and veterinary applications.

Clario / Thermo Fisher Scientific: The company reached a definitive agreement to be acquired by Thermo Fisher Scientific for $8.8 billion on October 29, 2025. The company is a provider of health outcomes research services and medical devices intended for biopharmaceutical sponsors and contract research organizations.

OrganOx / Terumo: The company was acquired by Terumo for $1.5 billion on October 31, 2025. The company is a developer and manufacturer of organ preservation and transplantation devices designed to reduce liver decay.

Tourmaline Bio / Novartis: The company was acquired by Novartis for $1.4 billion on October 28, 2025. Tourmaline Bio Inc is late-stage clinical biotechnology company developing novel immunomodulatory therapeutics for autoimmune and inflammatory diseases.

ANiGENT / Omnicell: The company was acquired by Omnicell for an undisclosed amount on October 27, 2025. The company is a developer of a drug diversion monitoring and controlled substance tracking software for detecting medication theft and misuse in healthcare facilities.

ARK Diagnostics / ARCHIMED: The company was acquired by Soulbrain and ARCHIMED through an estimated $428 million LBO on October 28, 2025. The company is a manufacturer of in vitro diagnostic immunoassays and therapeutic drug monitoring tests for measuring pharmaceutical drug concentrations in patient blood samples.

Noninvasix / Cypher Metaverse: The company reached a definitive agreement to be acquired by Cypher Metaverse and become publicly traded through a reverse merger on October 31, 2025. The company is a developer of an optoacoustic platform technology designed to non-invasively and continuously measure central venous saturation.

Redberry / Lonza Group: The company reached a definitive agreement to be acquired by Lonza Group for an undisclosed amount on October 27, 2025. The company is a developer of automated rapid microbial detection systems for quality control testing in water, food processing, and pharmaceutical manufacturing..

Wellspent / Babbel: The company was acquired by Babbel for an undisclosed amount on October 30, 2025. The company is a developer of digital wellbeing applications that monitor and reduce smartphone usage and screen time addiction.

OpenEvidence: The company raised $200 million of Series C venture funding in a deal led by GV on October 20, 2025, putting the company’s pre-money valuation at $5.8 billion. Coatue Management, Blackstone, BOND Capital, Thrive Capital, Sequoia Capital, Kleiner Perkins and Craft Ventures also participated in the round. The company is a developer of an AI-powered medical knowledge platform that aggregates, synthesizes, and provides access to clinical research and medical literature for healthcare professionals.

Electra Therapeutics: The company raised $183 million of Series C venture funding in a deal led by Nextech Invest and EQT Life Sciences on October 22, 2025, putting the company’s pre-money valuation at $296 million. Sanofi Ventures, OrbiMed, Redmile Group, Cormorant Asset Management, RA Capital Management, New Leaf Venture, HBM Healthcare Investments, Westlake Village BioPartners, Mubadala Capital and other undisclosed investors also participated in the round. The company is an operator of a biotechnology business intended for the treatment of immunological diseases and cancer.

CoMind: The company raised $102.5 million of venture funding in a deal led by Plural VC on October 20, 2025. Angelini Ventures, Latitude, Octopus Ventures, Phoenix Court, Backed VC, Entrepreneurs First, Lord David Prior, Approx.vc, Crane Investment Company, Plural Platform and other undisclosed investors also participated in the round. The company is a developer of a brain-computer interface technology and neural sensing systems for human-machine interaction applications.

Hyro: The company raised $45 million of Series B venture funding in a deal led by Healthier Capital on October 21, 2025, putting the company’s pre-money valuation at $199.5 million. Bon Secours Mercy Health, ServiceNow Ventures, Norwest, Define Ventures, and other undisclosed investors also participated in the round. The company is a developer of conversational artificial intelligence software that automates patient communication and healthcare call center operations.

NewLimit: The company raised $45 million of venture funding from Eli Lilly, Boost VC, Section 32 and Kleiner Perkins on October 20, 2025, putting the company’s pre-money valuation at $1.56 billion. Dimension (United States), Human Capital, Abstract Ventures and DUMAC (Durham) also participated in the round. The company is a developer of precision medicines designed for epigenetic reprogramming to restore youthful function in aging cells.

MarvelBiome: The company raised $39.5 million of venture funding from undisclosed investors on October 22, 2025. The company is an operator of a biopharmaceutical technology business intended to develop microbiome-based therapeutics using engineered bacteria for treating human diseases.

Elucid Bioimaging: The company raised $36.5 million of venture funding from undisclosed investors on October 22, 2025. The company is a developer of an artificial intelligence-powered medical imaging analysis software for cardiovascular disease diagnosis and risk assessment.

ReCode Therapeutics: The company raised $31 million of venture funding in the form of convertible debt from ABRDN Emerging Markets Equity Income and Cystic Fibrosis Foundation on October 23, 2025. The company is a developer of precision genetic medicine delivery systems for treating rare genetic diseases.

Valthos: The company raised $30 million of venture funding from OpenAI, Founders Fund, Definition and Lux Capital on October 24, 2025. The company is a developer of biological intelligence platforms using artificial intelligence to detect and counter emerging biosecurity threats and pandemics.

Faeth: The company raised $25 million of Series A venture funding in a deal led by S2G Investments on October 20, 2025, putting the company’s pre-money valuation at $26 million. KdT Ventures, Khosla Ventures, Future Ventures (San Francisco), Cantos Ventures, Digitalis Ventures, B Capital Group, Avicella Capital, THO Seed Fund, and other undisclosed investors also participated in the round. The company is a developer of precision nutrition therapies based on cancer metabolism research for oncology treatment support.

Catalyst OrthoScience: The company raised $15 million of Series G venture through combination of debt and equity in a deal led by RC Capital on October 22, 2025. Mutual Capital Partners, Derace Schaffer, and Western Alliance Bank also participated in the round. The company is a developer of minimally invasive shoulder arthroplasty systems and orthopedic surgical devices.

Vergent Bioscience: The company raised $18.6 million of Series C venture funding from undisclosed investors on October 20, 2025, putting the company’s pre-money valuation at $56.33 million. The company is a developer of molecular imaging probes designed for the diagnosis and removal of cancer cells.

Corner Therapeutics: The company raised $16.8 million of venture funding in the form of convertible notes from undisclosed investors on October 20, 2025. The company is a developer of T cell immunotherapies that generate durable memory T cell responses for long-lasting immunity against diseases.

Valink Therapeutics: The company raised $11.8 million of venture funding in a deal led by Redalpine on October 20, 2025. RV Invest, P53, LongeVC, Oxford Science Enterprises, Hoxton Ventures, and other undisclosed investors also participated in the round. The company is a developer of a modular protein platform designed to facilitate the scalable discovery of bi-specific biologics.

Agitated Solutions: The company raised $6.5 million of venture funding from undisclosed investors on October 22, 2025. The company is a developer of advanced ultrasound imaging technology intended to enhance clinical outcomes and diagnostic efficiency.

Burl Concepts: The company raised $4.5 million of venture funding in a deal led by James Brailean on October 21, 2025. K&K Vision and Acquipharma Holdings also participated in the round. The company is a developer of portable ultrasound devices for pre-hospital stroke detection and emergency medical diagnostics.

EpiBone: The company raised $4.3 million of venture funding from Impact Assets on October 24, 2025. The company is a developer of patient-specific bone grafts using tissue engineering and three-dimensional bioprinting for skeletal reconstruction.

Auxilium Biotechnologies: The company raised $3.5 million of venture funding from undisclosed investors on October 23, 2025. The company is an operator of a biotechnology business intended to help treat traumatic injuries of the nervous system.

Exeliom Biosciences: The company raised EUR 2.85 million of Series A venture funding in a deal led by Biocodex on October 21, 2025. UI Investissement, Forepont Capital Partners and CresVentures also participated in the round. The company is a developer of microbiome-derived immunotherapies that harness gut bacteria for therapeutic applications.

Mosaic Therapeutics: The company is in the process of raising Series B venture funding from undisclosed investors on October 20, 2025. The company is an operator of an oncology therapeutics business intended to treat cancers with substantial unmet needs.

Psylaris: The company raised an undisclosed amount of venture funding from LIOF Nedermaas High Tech Ventures, CbusineZ and Brightlands Venture Partners on October 22, 2025. Coöperatieve INZET I U.A. also participated in the round. The company is a developer of virtual reality-based therapeutic applications for treating post-traumatic stress disorder, anxiety, and trauma-related mental health conditions.

Sonus Microsystems: The company raised an undisclosed amount of venture funding from Providence Health Care Ventures, Supernode and Xavaav Capital on October 23, 2025. Other undisclosed investors also participated in this round. The company is a developer of a wearable cardiac ultrasound imaging technology device designed for remote monitoring and diagnostics.

Trevarx Biomedical: The company is in the process of raising venture funding on October 24, 2025. The company is a developer of a radiopharmaceutical platform designed to identify and treat cancers through targeted delivery of radioactive therapies.

Zag Bio: The company raised an undisclosed amount of venture funding from AbbVie Ventures, Boxer Capital and Macroscopic Ventures in August 2025. Exitfund and Lightspeed Ventures also participated in the round. The company is an operator of a therapeutic platform intended to offer precise medicines for immune-mediated diseases.

Hologic / Blackstone: The company entered into a definitive agreement to be acquired by Blackstone, TPG, Abu Dhabi Investment Authority and GIC Private through an estimated $18.3 billion public-to-private LBO on October 21, 2025. Hologic manufactures diagnostic imaging systems, surgical devices, and women’s health medical technologies including mammography and diagnostic testing products.

Avidity Biosciences / Novartis: The company reached a definitive agreement to be acquired by Novartis for $12 billion on October 26, 2025. Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs.

Avadel Pharmaceuticals / Alkermes: The company reached a definitive agreement to be acquired by Alkermes for $2.1 billion on October 22, 2025. Avadel Pharmaceuticals PLC is a specialty pharmaceutical company developing and commercializing therapies for sleep disorders and other neurological conditions.

Adverum Biotechnologies / Eli Lilly: The company reached a definitive agreement to be acquired by Eli Lilly for an undisclosed amount on October 24, 2025. Adverum Biotechnologies Inc is a clinical-stage gene therapy company developing adeno-associated virus (AAV) therapies for ocular diseases including diabetic macular edema.

ImCheck Therapeutics / Ipsen: The company reached a definitive agreement to be acquired by Ipsen for up to EUR 1.0 billion as of October 22, 2025. The company is a developer of immune checkpoint modulatory antibodies for cancer immunotherapy and immune-related disease applications.

Toku / Topcon Healthcare Solutions: The company was acquired by Topcon Healthcare Solutions for an undisclosed amount on October 20, 2025. The company is a developer of artificial intelligence-powered diagnostic tools that analyze retinal images to detect cardiovascular disease, chronic kidney disease, and other systemic health conditions.

Wilmington PharmaTech Company / Curewell Capital: The company was acquired by Curewell Capital through an LBO on October 21, 2025 for an undisclosed amount. The company is a provider of contract research, development, and manufacturing services for pharmaceutical and biotechnology drug development.

Kailera Therapeutics: The company is in the process of raising $600 million of an undisclosed targeted amount of Series B venture funding in a deal led by Bain Capital on October 14, 2025. Bain Capital Life Sciences, Canada Post Pension Plan, Sirona, Royalty Pharma, The Invus Group, Atlas Venture, RTW Investments, Adage Capital Management, Janus Henderson Investors, Perseverance Capital Management, Qatar Investment Authority and Surveyor Capital also participated in the round. The company is an operator of a biopharmaceutical business intended to deliver differentiated treatment options for obesity and related conditions.

Tubulis: The company raised $361 million of Series C venture funding in a deal led by Venrock on October 15, 2025. Andera Partners, Frazier Healthcare Partners, Ascenta Capital, Fund+, EQT Life Sciences, Nextech Invest, Deep Track Capital, High-Tech Gründerfonds, Seventure Partners, Bayern Kapital, OCCIDENT and Wellington Management also participated in the round. The company is a developer of chemotherapeutic drugs designed to fight cancer and chronic diseases.

Kardigan: The company raised $254 million of Series B venture funding from Sequoia Heritage, ARCH Venture Partners, and Fidelity Management & Research Company on October 14, 2025. T. Rowe Price Group also participated in the round. The company is a developer of cardiovascular therapeutics and drug discovery platforms for heart disease treatment.

HistoSonics: The company received $250 million of development capital from Thiel Bio, Founders Fund and other investors on October 16, 2025. The company is a developer of robotically-assisted ultrasound technology for non-invasive tissue ablation and tumor destruction.

VeraDermics: The company raised $150 million of Series C venture funding in a deal led by SR One Capital Management on October 16, 2025, putting the company’s pre-money valuation at $140 million. LifeSci Venture Partners, The Invus Group, Infinitium (VC), Longitude Capital, Surveyor Capital, Viking Global Investors, Marshall Wace, Suvretta Capital Management, Columbia Management and Aberdeen Investments (Scotland) also participated in the round. The company is a developer of aesthetics and dermatology-focused drugs intended to address common dermatologic conditions.

Adcytherix: The company raised EUR 105 million of Series A venture funding in a deal led by Angelini Ventures, Andera Partners, Bpifrance and Kurma Partners on October 16, 2025. Dawn Biopharma, Pontifax Venture Capital, Pureos Bioventures, RA Capital Management, aMoon Fund and Surveyor Capital also participated in the round. The company is a developer of an antibody-drug conjugate platform designed to address resistance and improve safety in cancer therapy through novel payload innovation.

Pelage: The company raised $120 million of Series B venture funding in a deal led by GV and ARCH Venture Partners on October 15, 2025, putting the company’s pre-money valuation at $203 million. Main Street Advisors, Visionary Venture Fund and YK Bioventures also participated in the round. The company is a developer of small molecule therapeutics targeting hair follicle stem cell metabolism for treating androgenetic alopecia and hair loss.

Peptilogics: The company raised $78 million of Series B venture funding in a deal led by Presight Capital, Founders Fund and Thiel Bio on October 16, 2025. Narya, Beyond Ventures and AMR Action Fund also participated in the round. The company is a developer of a novel peptide therapeutic drug discovery platform designed to treat multidrug-resistant bacterial infections.

Tr1x: The company raised $50 million of venture funding from undisclosed investors on October 15, 2025. The company is a developer of a regulatory T cell-based therapy platform designed to treat autoimmune and inflammatory diseases by restoring immune tolerance.

Step Pharma: The company raised EUR 38 million of Series C venture funding in a deal led by V-Bio Ventures on October 15, 2025. Kurma Partners, Pontifax Venture Capital, Hadean Ventures, Inserm Transfert and Sunstone Life Science Ventures also participated in the round. The company is a developer of proprietary small molecule therapeutics designed for the treatment of auto-immune diseases.

Intelligent Locations: The company raised an estimated $35 million of Series A venture funding from Marlin Equity Partners, First Analysis and other undisclosed investors on October 14, 2025, putting the company’s pre-money valuation at $45 million. The company is a developer of an artificial intelligence-embedded tracking technology designed to provide data insights for healthcare organizations.

BridGene Biosciences: The company raised $28 million of Series B venture funding in a deal led by Bayland Capital and Kangjun Capital on October 16, 2025. Pangu Venture, Lapam Capital, Shenzhen GTJA Investment Group, Proxima Investments and Grains Valley Venture Capital also participated in the round. The company is a developer of chemoproteomics-based drug discovery platforms targeting previously undruggable proteins for therapeutic development.

Brook: The company raised $28 million of Series B venture funding in a deal led by Morningside Group and UMass Memorial Health Care on October 16, 2025. Other undisclosed investors also participated in the round. The company is a developer of digital chronic disease management programs combining remote monitoring, coaching, and care coordination for diabetes and metabolic conditions.

Pheast Therapeutics: The company raised $24.6 million of venture funding from undisclosed investors on October 15, 2025. The company is a provider of macrophage-targeted immunotherapies intended for cancer treatment.

Sage Care: The company raised $20 million of venture funding in a deal led by Yosemite on October 17, 2025, putting the company’s pre-money valuation at $70 million. Metrodora, SV Angel, Liquid 2 Ventures, Seven Stars Ventures, refract ventures, AME Cloud Ventures, Apollo Ono, OVTR VC and General Catalyst also participated in the round. The company is a developer of an artificial intelligence-powered healthcare navigation software that matches patients with appropriate specialists and care providers.

Weave: The company raised $20 million of Series A venture funding in a deal led by U.S. Venture Partners on October 16, 2025. Innovation Endeavors, Magnetic Ventures, TMV (Trail Mix Ventures), Character, and Serrado Capital also participated in the round. The company is a developer of an artificial intelligence-powered software for automating regulatory submissions and clinical trial documentation.

Mission Therapeutics: The company raised $13.3 million of venture funding in a deal led by Roche Venture Fund, Sofinnova Partners, SR One Capital Management, Rosetta Capital, Pfizer Ventures and IP Group on October 15, 2025. The company is an operator of a pharmaceutical research and drug discovery business intended to facilitate the development of advanced medical treatments.

EVerZom: The company raised EUR 10 million of venture funding from Capital Grand Est, Sorbonne Venture and European Innovation Council on October 14, 2025, putting the company’s pre-money valuation at an estimated EUR 13.5 million. Paris Business Angels, Capital Cell and other undisclosed investors also participated in the round. The company is a developer of a regenerative biologics treatment designed for tissue healing and organ restoration.

Smartlens: The company raised $5.2 million of venture funding in a deal led by Ambit Health Ventures on October 14, 2025. Boutique Venture Partners, Graphene Ventures, and HBS Alumni Angels of Greater New York also participated in the round. The company is a developer of a wearable device intended to prevent the progression of glaucoma and irreversible blindness.

ARC Medical: The company closed on $5 million of an undisclosed targeted amount of venture funding from Lumina Growth Partners and other undisclosed investors on October 16, 2025, putting the company’s pre-money valuation at $45 million. The company is a manufacturer of clinical therapeutic equipment designed to reduce surgical adhesions in humans.

BlueWhale Bio: The company raised $5 million of venture funding from undisclosed investors on October 16, 2025. The company is a developer of a cell therapy manufacturing platform and bioprocessing technology for scaling gene therapy production.

TachyHealth: The company raised $5 million of Series A venture funding in a deal led by The Company for Cooperative Insurance on October 14, 2025. Other undisclosed investors also participated in the round. The company is a developer of an artificial intelligence-powered healthcare analytics software for value-based care contracting and provider-payer integration.

Clinware: The company raised $4.25 million of venture funding from undisclosed investors on October 14, 2025. The company is a developer of healthcare automation software designed for streamlining clinical and financial workflows.

SMSbiotech: The company is in the process of raising venture funding on October 15, 2025. The company is a developer of a patented stem cell therapy designed to advance regenerative medicine through a novel class of human allogeneic adult stem cells.

Astria Therapeutics / BioCryst Pharmaceuticals: The company reached a definitive agreement to be acquired by BioCryst Pharmaceuticals for $700 million on October 14, 2025. Astria Therapeutics Inc is a biopharmaceutical company developing therapeutics for rare allergic and immunological diseases including hereditary angioedema.

Nalu Medical / Boston Scientific: The company reached a definitive agreement to be acquired by Boston Scientific for an estimated $533 million on October 17, 2025. The company is a developer of a neurostimulation implant designed to provide long-term relief for patients with intractable chronic nerve pain.

Aculys / Viatris: The company was acquired by Viatris for an undisclosed amount on October 15, 2025. The company is an operator of a clinical-stage biopharmaceutical business developing therapeutics for neurological and psychiatric disorders in the Japanese market.

Happypillar / Manatee: The company was acquired by Manatee for an undisclosed amount on October 17, 2025. The company is a developer of digital mental health applications providing therapy and support resources for families and children.

Ikerian / EssilorLuxottica: The company was acquired by EssilorLuxottica, a subsidiary of EssilorLuxottica Société, for an undisclosed amount on October 15, 2025. The company is a developer of an ophthalmology intelligence platform designed to accelerate clinic, research, and pharmaceutical workflows.

Panda Health / AVIA: The company was acquired by AVIA for an undisclosed amount on October 15, 2025. The company is an operator of a digital health marketplace platform that evaluates and recommends digital therapeutics and health applications.

Phare Health / R1 RCM: The company reached a definitive agreement to be acquired by R1 RCM, via its financial sponsors TowerBrook Capital Partners, Khosla Ventures and Clayton, Dubilier & Rice, through an LBO on October 14, 2025 for an undisclosed amount. The company is a developer of an artificial intelligence-powered clinical documentation software that captures and codes patient care data for hospital billing.

Renaissance Lakewood / LTS Lohmann Therapie-Systeme: The company entered into a definitive agreement to be acquired by LTS Lohmann Therapie-Systeme, via its financial sponsor Dievini, through LBO on October 13, 2025 for an undisclosed amount. The company is a manufacturer of nasal spray drug delivery systems and provides formulation development and stability testing services.

Renee / Cairns Health: The company was acquired by Cairns Health for an undisclosed amount on October 17, 2025. The company is a developer of artificial intelligence-driven digital health assistants that automate patient communication and healthcare administrative tasks.

ZepMed / Cortechs.ai: The company was acquired by Cortechs.ai for an undisclosed amount on October 14, 2025. The company is a developer of artificial intelligence-powered medical imaging analysis and clinical decision support software for healthcare providers.

TORL BioTherapeutics: The company raised $96 million of Series C venture funding from undisclosed investors on October 7, 2025. The company is a drug development business designed to focus on antibody-drug conjugates and other biologics.

Trogenix: The company raised GBP 70 million of Series A venture funding in a deal led by IQ Capital Partners on October 6, 2025. Eli Lilly, Calculus Capital, Meltwind Advisory, LongeVC, 4BIO Capital, Cancer Research Horizons and The Brain Tumor Investment Fund also participated in the round. The company is an operator of a proprietary gene therapy platform intended for technologies in genomics, synthetic biology, sophisticated oncology disease models, advanced gene therapy systems, and immunotherapy.

ObjectiveHealth: The company raised $47.2 million of venture funding from undisclosed investors on October 8, 2025. The company is a developer of clinical research software that integrates real-world evidence and point-of-care data to improve patient outcomes.

Sensi.AI: The company raised $45 million of Series C venture funding in a deal led by Qumra Capital on October 9, 2025. Flint Capital, Entrée Capital, Jibe Ventures, Zeev Ventures, and Insight Partners also participated in the round. The company is a developer of ambient audio monitoring technology that detects behavioral and physiological abnormalities in elderly and cognitively impaired patients to prevent adverse events.

Affinia Therapeutics: The company raised $40 million of Series C venture funding in a deal led by New Enterprise Associates on October 7, 2025, putting the company’s pre-money valuation at $105 million. GV, Eli Lilly, Atlas Venture, Alexandria Venture Investments, Mass General Brigham Ventures, F-Prime Capital, Perceptive Advisors, Avidity Partners, and other undisclosed investors also participated in the round. The company is a developer of an adeno-associated virus gene therapy platform intended to focus on diseases affecting the central nervous system and muscles.

Lumen Bioscience: The company raised $30 million of Series C venture funding in a deal led by WestRiver Group on October 8, 2025. The Gates Foundation and other undisclosed investors also participated in the round. The company is a developer of a spirulina-based biomanufacturing technology for producing therapeutic proteins and biologic drugs at reduced cost.

Phagos: The company raised EUR 25 million of Series A venture funding in a deal led by Demeter Partners, Capagro, Hoxton Ventures and CapHorn Invest on October 8, 2025. Entrepreneurs First, Acurio Ventures Partners, Founders Capital, Station F and Citizen Capital also participated in the round. The company is an operator of a biotechnology research business intended to provide customizable drugs to replace antibiotics in animal farming.

Goodpath: The company raised $18 million of Series A venture funding in a deal led by MassMutual Ventures on October 6, 2025, putting the company’s pre-money valuation at $23 million. Healthy Ventures and other undisclosed investors also participated in the round. The company is a developer of a personalized self-care program designed to improve the lives of people managing chronic conditions.

Curadel Pharma: The company raised $14.5 million of venture funding from undisclosed investors on October 9, 2025. The company is a developer of optical imaging systems for intraoperative visualization and surgical guidance applications.

Peer: The company raised $12.1 million of venture funding in a deal led by Flare Capital Partners and SignalFire on October 7, 2025. Atria Ventures, Greycroft, Alumni Ventures, Gaingels, Mana Ventures and other undisclosed investors also participated in the round. The company is a developer of an artificial intelligence-powered medical writing software that accelerates clinical trial documentation and regulatory submissions.

Mati Therapeutics: The company raised $12 million of Series A venture funding from undisclosed investors on October 8, 2025. The company is a developer of a novel, non-invasive sustained drug delivery platform designed to deliver medication to the surface of the eye for improved treatment of ocular conditions.

ThirdLaw Molecular: The company raised $5.5 million of venture funding from undisclosed investors on October 8, 2025. The company is a developer of a synthetic technology and computational chemistry platform designed for spiroligomers and other unnatural molecules.

Somatix: The company raised $3.94 million of venture funding in the form of convertible debt from undisclosed investors on October 9, 2025. The company is a developer of an artificial intelligence-powered wearable sensor for continuous remote patient monitoring and early health intervention.

Beren Therapeutics: The company raised an undisclosed amount of venture funding from JIC Venture Growth Investments and UTokyo Innovation Platform Company on October 7, 2025. The company is an operator of a biotechnology business intended to develop novel biologic therapeutics for treating rare and underserved diseases.

Byonyks Medical Devices: The company is in the process of raising Series A venture funding on October 10, 2025, putting the company’s post-valuation at $250 million. The company is a developer of a low-cost device designed to perform home-based peritoneal dialysis for treating kidney failure.

Informed Mindset Medical: The company raised an undisclosed amount of venture funding in a deal led by Grayhawk Capital and AZ Venture Capital on October 8, 2025. Xcellerant Ventures also participated in the round. The company is a developer of a digital health platform that collects and analyzes real-time patient-reported outcomes and biometric data.

SQ Innovation: The company raised an undisclosed amount of Series B venture funding in a deal led by Marco van der Poel on October 7, 2025. The company is a developer of FDA-cleared medical devices for clinical therapeutic applications.

Verona Pharma / Merck & Co.: The company was acquired by Merck & Co. for $10 billion on October 7, 2025. The company is an operator of a clinical-stage biopharmaceutical business intended to develop therapies for chronic respiratory diseases including COPD and asthma.

Press Ganey Associates / Qualtrics: The company entered into a definitive agreement to be acquired by Qualtrics, via its financial sponsors Accel, CPP Investments, DFO Management, Harbert Management, Silver Lake, SoftBank Investment Advisers and Susquehanna Growth Equity, through a $6.7 billion LBO on October 6, 2025. The company is a provider of patient experience measurement, performance analytics, and healthcare quality improvement consulting services.

Akero Therapeutics / Novo Nordisk: The company reached a definitive agreement to be acquired by Novo Nordisk for up to $5.2 billion on October 9, 2025. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs.

Orbital Therapeutics / Bristol-Myers Squibb: The company reached a definitive agreement to be acquired by Bristol-Myers Squibb for $1.5 billion on October 10, 2025. The company is a developer of an RNA therapeutic platform integrating multiple delivery mechanisms for genetic medicine applications.

ScPharmaceuticals / MannKind: The company was acquired by MannKind for up to $360 million on October 7, 2025. ScPharmaceuticals Inc is a pharmaceutical company focused on developing subcutaneous infusion systems and self-administered therapies for cardiovascular and other chronic conditions.

DigitalOwl / Datavant: The company was acquired by Datavant, via its financial sponsors Town Hall Ventures, Oxeon Partners, New Mountain Capital and Ardan Equity, through an estimated $200 million LBO on October 8, 2025. The company is a developer of a natural language processing platform designed to provide an efficient process of reviewing medical records.

Monogram Technologies / Zimmer Biomet Holdings: The company was acquired by Zimmer Biomet Holdings for an equity value of $177 million on October 7, 2025. Monogram Technologies Inc develops patient-specific orthopedic implants using 3D printing, robotics, and pre-operative imaging integration.

Diatech Diabetes / DEKA Research & Development: The company was acquired by DEKA Research & Development for an undisclosed amount on October 7, 2025. The company is a developer of a monitoring platform designed to personalize insulin delivery for patients with diabetes.

ESSA / XenoTherapeutics: The company was acquired by XenoTherapeutics for an undisclosed amount on October 9, 2025. ESSA Pharma Inc is a pharmaceutical company focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer.

MindMaze / Relief Therapeutics Holding: The company reached a definitive agreement to be acquired by Relief Therapeutics Holding, a subsidiary of Sonnet BioTherapeutics, through a CHF 1 billion reverse merger on October 8, 2025. The company is a developer of digital therapeutics and neurotechnology devices that facilitate neurological recovery, motor learning, and cognitive rehabilitation.

Overlook Industries / Enpro: The company was acquired by Enpro for an undisclosed amount on October 8, 2025. The company is a manufacturer of precision dispensing needles and fluid delivery components for medical device and pharmaceutical applications.

Polynoma / TransCode Therapeutics: TransCode Therapeutics reached a definitive agreement to acquire the company, a subsidiary of CK Life Sciences International, for an undisclosed amount on October 8, 2025. The company is a developer of an immuno-oncology vaccine focused on the treatment of melanoma.

Virsys12 / HealthStream: The company was acquired by HealthStream for up to $17 million on October 8, 2025. The company provides Salesforce implementation and integration consulting services for healthcare technology systems.